Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-04-30 DOI:10.3324/haematol.2024.287090

Lok Lam Ngai,Tom Reuvekamp,Diana Hanekamp,Fleur Janssen,Laura Oudshoorn-van Marsbergen,Jannemieke Carbaat-Ham,Maaike A M Hofland,Mona M H E Fayed,Angèle Kelder,Willemijn J Scholten,Alexander N Snel,Costa Bachas,Jesse M Tettero,Dimitri A Breems,Thomas Fischer,Bjørn T Gjertsen,Laimonas Griškevičius,Gunnar Juliusson,Arjan A Van de Loosdrecht,Johan A Maertens,Markus G Manz,Thomas Pabst,Jakob R Passweg,Kimmo Porkka,Peter J M Valk,Patrycja Gradowska,Bob Löwenberg,Gert J Ossenkoppele,David C De Leeuw,Jacqueline Cloos

{"title":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.","authors":"Lok Lam Ngai,Tom Reuvekamp,Diana Hanekamp,Fleur Janssen,Laura Oudshoorn-van Marsbergen,Jannemieke Carbaat-Ham,Maaike A M Hofland,Mona M H E Fayed,Angèle Kelder,Willemijn J Scholten,Alexander N Snel,Costa Bachas,Jesse M Tettero,Dimitri A Breems,Thomas Fischer,Bjørn T Gjertsen,Laimonas Griškevičius,Gunnar Juliusson,Arjan A Van de Loosdrecht,Johan A Maertens,Markus G Manz,Thomas Pabst,Jakob R Passweg,Kimmo Porkka,Peter J M Valk,Patrycja Gradowska,Bob Löwenberg,Gert J Ossenkoppele,David C De Leeuw,Jacqueline Cloos","doi":"10.3324/haematol.2024.287090","DOIUrl":null,"url":null,"abstract":"In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across ELN2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we have evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that acquiring 1 million white blood cells is essential for accurate LSC-negativity assessment. Among different LSC markers, CD44 overexpression on CD34+CD38- cells was the only insignificant marker in our panel. Testing the impact of several published variations on the analysis for LSC assessments on prognostic value for overall survival and cumulative incidence of relapse, showed marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight in the different methods of LSC definition can facilitate the clinical implementation.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"8 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.287090","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across ELN2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we have evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that acquiring 1 million white blood cells is essential for accurate LSC-negativity assessment. Among different LSC markers, CD44 overexpression on CD34+CD38- cells was the only insignificant marker in our panel. Testing the impact of several published variations on the analysis for LSC assessments on prognostic value for overall survival and cumulative incidence of relapse, showed marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight in the different methods of LSC definition can facilitate the clinical implementation.

查看原文本刊更多论文

强化治疗患者急性髓系白血病干细胞定量的不同特征。

在急性髓系白血病中，CD34+CD38-白血病干细胞（LSC）负荷在诊断和诱导化疗后具有预后价值。由于已经提出了不同的LSC量化方法，我们使用来自HOVON-SAKK132试验的数据，确定了这些方法在ELN2017风险组中对总生存率和复发率的预后价值。此外，我们还评估了准确检测LSC的最佳获得白细胞数量和单个LSC标记物的预后价值。结果表明，获得100万个白细胞是准确评估lsc阴性的必要条件。在不同的LSC标志物中，CD34+CD38-细胞上的CD44过表达是我们小组中唯一不显著的标志物。对几个已发表的LSC评估对总生存期和累积复发率的预后价值分析的影响进行了测试，显示出边际差异，证明了LSC负担的强大预后价值。为了进一步的临床实施，最佳LSC评估可能因ELN风险组而异。总之，LSC负担是一个可靠的预后因素，了解LSC定义的不同方法可以促进临床实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.